AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04752111
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery
Trial: NCT06590493
Drug: doxecitine and doxribtimine
RxNorm normalized name: Doxecitine
DrugBank: 2'-Deoxycytidine (DB02594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TK0113 and TK0115: Doxecitine and doxribtimine is dosed daily and will be administered orally or via feeding tube. The patient may continue to receive doxecitine and doxribtimine treatment within the EAP as long as the benefit / risk balance remains positive in the opinion of the treating physician or access to commercially available doxecitine and doxribtimine, when it becomes available.
Trial: NCT06595355
Drug: bevacizumab with oral curcumin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: According to the recommendation of the American Association of Ophthalmologists, intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the simultaneous intervention group, patients will take daily curcumin tablets (sinacurcumin product) at a dose of 40 mg twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
Trial: NCT06595355
Drug: bevacizumab with oral placebo
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the control group, patients will be taking daily placebo tablets twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
Trial: NCT06592131
Drug: BF844
RxNorm normalized name: BF844
DrugBank: BF-844 (DB17801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.
Trial: NCT06594874
Drug: HS-10370
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10370 administered orally every day
Trial: NCT06594874
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously every 21 days; dose by label.
Trial: NCT06594874
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously every 21 days; dose by label.
Trial: NCT06594874
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously every 21 days; dose by label.
Trial: NCT06594874
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously every 21 days; dose by label.
Trial: NCT06595563
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: T-DM1 will be administered IV at a dose of 3.6 mg/kg every 3 weeks. (21 days +/- 3 days) until disease progression, unacceptable toxicity or request of the subject to withdraw from the study. The total dose will depend on the subject's weight on day 1 of each T-DM1 cycle.
Trial: NCT06590896
Drug: Cenobamate
RxNorm normalized name: Cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cenobamate will be orally administered once daily.
Trial: NCT06588036
Drug: Prebiotic
RxNorm normalized name: Prebiotic Inulin-FOS
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: . The primary outcome measure will be the mean time from the initiation of treatment to the resolution of diarrhea symptoms. This objective seeks to provide evidence-based insights into the optimal management strategies for childhood diarrhea and inform clinical practice guidelines.
Trial: NCT06715891
Drug: Raphamin
RxNorm normalized name: Allantoin 0.007 g in 0.7 g TOPICAL POWDER [RAPHAGEN POWDE R]
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral use.
Trial: NCT06724263
Drug: B1962
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: B1962 has higher VEGF anti angiogenic activity than its competitors. Phase I clinical trials have shown that B1962 has excellent safety and promising therapeutic effects. Large scale clinical studies may achieve better therapeutic effects than similar competitors targeting the same target
Trial: NCT06724042
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
Trial: NCT06724042
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
Trial: NCT06724042
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
Trial: NCT00511966
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT05248633
Drug: Bortezomib Injection
RxNorm normalized name: bortezomib Injection
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous Bortezomib 1.3mg/m2 d1,8,15,22
Trial: NCT05248633
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 25mg for 21 days
Trial: NCT05248633
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40mg d1,8,15,22
Trial: NCT05649020
Drug: Dose of prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
Trial: NCT05005715
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
Trial: NCT05040295
Drug: ritlecitinib
RxNorm normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intact adult capsule
Trial: NCT05040295
Drug: ritlecitinib
RxNorm normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg pediatric capsule
Trial: NCT05040295
Drug: ritlecitinib
RxNorm normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg spray congealed beads
Trial: NCT05587621
Drug: statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dietary advice for low cholesterol food
Trial: NCT06090422
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
Trial: NCT06090422
Drug: Midazolam Hydrochloride
RxNorm normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
Trial: NCT06596343
Drug: Adjuvant Chemotherapy Combined with Traditional Chinese Medicine (TCM) Supportive Therapy
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Chemotherapy Regimen:~   * Postoperative adjuvant chemotherapy: A dual-drug concurrent regimen will be used, with each cycle lasting 21 days. On day 1 of each cycle, oxaliplatin will be administered intravenously at a dose of 130 mg/m². From day 1 to day 14 of each cycle, capecitabine will be taken orally at a dose of 1000 mg/m², twice daily. The treatment duration will follow the CSCO 2023 guidelines for colorectal cancer, with chemotherapy lasting for 6 months.~2. TCM Treatment:~   * TCM treatment will be based on syndrome differentiation (Zheng) and guided by the Guidelines for TCM Diagnosis and Treatment of Malignant Tumors.
Trial: NCT06592287
Drug: Adebrelimab + Apatinib + Lrinotecan liposome
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab 1200 mg, iv. q3w~Apatinib 250 mg po qd~Lrinotecan liposome 80mg/m2, iv. q3w~Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years.
Trial: NCT06592326
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab, 240mg, intravenous (IV) infusion
Trial: NCT06592326
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine: 1000mg/m2, intravenous (IV) infusion
Trial: NCT06592326
Drug: Cisplatin/Carboplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.
Trial: NCT06586242
Drug: Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w
Trial: NCT06161766
Drug: terlipressin or noradrenalin plus albumin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed CKD who had received vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.
Trial: NCT04852172
Drug: L-citrulline
RxNorm normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.
Trial: NCT05767749
Drug: Ropivacaine 0.5% Injectable Solution
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 ml Ropivacaine 0.5% Injectable Solution
Trial: NCT05767749
Drug: Bupivacaine 0.5% Injectable Solution
RxNorm normalized name: BUPivacaine 0.5% injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5ml bupivacaine 0.5%
Trial: NCT06592625
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811
Trial: NCT06592625
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab
Trial: NCT06590155
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy
Trial: NCT06603376
Drug: FOLFIRI + Vemurafenib + Cetuximab
RxNorm normalized name: Vemurafenib
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Cetuximab: 500 mg/m², intravenous infusion over at least 2 hours, on day 1; Vemurafenib: 720 mg, orally twice daily. Repeat every 2 weeks.
Trial: NCT06603376
Drug: FOLFIRI ± Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Bevacizumab: 5 mg/kg, intravenous infusion, on day 1. Repeat every 2 weeks.
Trial: NCT06591299
Drug: Cilostazol 100 MG
RxNorm normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
Trial: NCT06591299
Drug: Clopidogrel 75mg
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
Trial: NCT06594640
Drug: Mitoxantrone Hydrochloride Liposome
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: assigned dose according to the 3+3 dose-escalation design in part 1, RP2D in part 2, D2
Trial: NCT06594640
Drug: Rituximab (R)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375mg/m2, D2
Trial: NCT06594640
Drug: Vincristin
RxNorm normalized name: Vincristin
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.2mg/m2, maximum 2mg， D2
Trial: NCT06604065
Drug: AMS2434 (amino acids)
RxNorm normalized name: silk amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The proprietary composition includes leucine, valine, isoleucine, lysine, phenylalanine, threonine, tyrosine, histidine, and methionine. Small amounts of non-caloric flavorings are also included.
Trial: NCT05083975
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20% benzocaine gel (Opahl Topical Gel)
Trial: NCT05116410
Drug: HS-20094
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated SC
Trial: NCT05387239
Drug: VL-PX10 and VL-P22 plus standard care
RxNorm normalized name: VL-2397
DrugBank: VL-2397 (DB17796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment consists of administration of VL-P22 and VL-PX10 plus standard care
Trial: NCT05430399
Drug: utidelone
RxNorm normalized name: Utidelone
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Trial: NCT05430399
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Trial: NCT06175806
Drug: Ondansetron Oral Film
RxNorm normalized name: Ondansetron Oral Film
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptamine (5-HT) receptor antagonist
Trial: NCT06175806
Drug: Granisetron Oral Liquid Product
RxNorm normalized name: granisetron Oral Liquid Product
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptamine (5-HT) receptor antagonist
Trial: NCT03110523
Drug: X0002
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All subjects who provide informed consent will initiate the Screening Period of at least 14 (±3) days for the assessment of eligibility including radiographic evaluation of the lumbar spine. X-ray images must be collected within 4-11 hours after the subject wakes up. Those subjects who meet preliminary eligibility criteria will be treated with placebo in a subject-blind manner for 14(±3) days from Screening Visit to Day 1. Subjects with a placebo response exceeding 25% improvement in the average NPRS score over the previous 7 days will be excluded. Subjects with a Lane grading of 1 or 2 on their neutral lateral lumbar spine film per the central radiologist are eligible to be enrolled. At Day 1, eligible subjects will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio with a 1:1 ratio of active:placebo within each treatment group, and stratified evenly according to Lane Radiographic Grading Scale summary score (1 or 2) and gender.
Trial: NCT04513223
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are six pre-defined dose regimens . Subjects will be enrolled with an initial dose
Trial: NCT05626621
Drug: Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray
RxNorm normalized name: azelastine hydrochloride Nasal Spray
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will follow this medication regimen for 6 months.
Trial: NCT05626621
Drug: Mometasone Nasal Irrigation (1 mg capsule)
RxNorm normalized name: mometasone Nasal Product
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will follow this medication regimen for 6 months.
Trial: NCT05626621
Drug: Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation
RxNorm normalized name: azelastine Nasal Product
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will follow this medication regimen for 6 months.
Trial: NCT01452698
Drug: TAK-438
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
Trial: NCT01452698
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks.
Trial: NCT04725240
Drug: Setmelanotide
RxNorm normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Setmelanotide for SC injection
Trial: NCT05577507
Drug: Cholestyramine Resin 4000 MG [Questran]
RxNorm normalized name: cholestyramine resin 4000 MG [Questran]
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cholestyramine 4 gram sachets (questran) will be administered orally three times daily for 8 weeks period trial
Trial: NCT05122338
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Trial: NCT05122338
Drug: Compound lidocaine
RxNorm normalized name: BENZOIN COMPOUND
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Trial: NCT06089265
Drug: PF-06801591
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ketohexokinase inhibitor
Trial: NCT05122338
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Before the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral transversus abdominis plane block
Trial: NCT05074992
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.